Novo Nordisk’s new diabetes drug Victoza proved more effective than Merck & Co’s Januvia in a head-to-head study published, in the Lancet.
The 26-week trial showed that Victoza produced significantly greater reductions in HbA1C, fasting plasma glucose and body weight than Januvia, with similar or better overall treatment satisfaction.
According to a Novo Nordisk announcement significantly more patients achieved the HbA_1c targets of <7·0% (American Diabetes Association [ADA]). Nearly twice as many study participants on Victoza reached the ADA goal compared to the Januvia group.